nelfinavir has been researched along with thiazoles in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Blanchard, SG; Furfine, ES; Ittoop, O; Jain, RG; Lenhard, JM; Orband-Miller, LA; Paulik, MA; Weiel, JE | 1 |
| Freire, E; Vega, S; Velazquez-Campoy, A | 1 |
| Grasela, DM; Kanamaluru, V; Marino, MR; O'Mara, EM; Smith, RA; Yan, JH | 1 |
| Branquinha, MH; d'Avila-Levy, CM; Pedroso e Silva, CM; Santos, AL; Santos, LO; Vitório, BS | 1 |
| Barlow, A; Barlow, B; Claassen, CW; Heavner, JJ; Heavner, MS; Landolf, KM; Yeung, SYA | 1 |
1 review(s) available for nelfinavir and thiazoles
| Article | Year |
|---|---|
Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Immunomodulation; Interferon-alpha; Lopinavir; Nelfinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; Purines; Pyrazoles; Ribavirin; Ritonavir; SARS-CoV-2; Sulfonamides; Thiazoles | 2020 |
1 trial(s) available for nelfinavir and thiazoles
| Article | Year |
|---|---|
The effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers.
Topics: Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Cytochrome P-450 CYP3A; Drug Interactions; Half-Life; Humans; Male; Middle Aged; Nelfinavir; Thiazoles; Triazoles | 2006 |
4 other study(ies) available for nelfinavir and thiazoles
| Article | Year |
|---|---|
HIV protease inhibitors block adipogenesis and increase lipolysis in vitro.
Topics: Adipocytes; Animals; Azo Compounds; Bexarotene; Carbamates; Carrier Proteins; Cell Differentiation; Cells, Cultured; Coloring Agents; Fatty Acid-Binding Proteins; Furans; HIV Protease Inhibitors; Indinavir; Insulin; Lipolysis; Lipoprotein Lipase; Nelfinavir; Neoplasm Proteins; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Ritonavir; RNA, Messenger; Rosiglitazone; Saquinavir; Stem Cells; Sulfonamides; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2000 |
Protease inhibitor trials moving to next phase.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Nelfinavir; Quinolines; Ritonavir; Saquinavir; Stavudine; Thiazoles; Valine; Virus Replication | 1995 |
Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
Topics: Africa; Amides; Amino Acid Substitution; Anti-HIV Agents; Calorimetry; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Kinetics; Mutagenesis, Site-Directed; Nelfinavir; Phenotype; Polymorphism, Genetic; Recombinant Proteins; Ritonavir; Saquinavir; Thermodynamics; Thiazoles | 2002 |
Nelfinavir is effective in inhibiting the multiplication and aspartic peptidase activity of Leishmania species, including strains obtained from HIV-positive patients.
Topics: Antiprotozoal Agents; Aspartic Acid Proteases; Colorimetry; Fluorometry; HIV Infections; Humans; Leishmania; Leishmaniasis; Microbial Viability; Nelfinavir; Oligopeptides; Saquinavir; Tetrazolium Salts; Thiazoles | 2013 |